#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Endologix CFO Shelley Thunen to resign

Share on Twitter Share on LinkedIn
Staff writer | Irvine, Ca., USA | March 13, 2015
EndologixMarch 13, 2015, Irvine, Ca., USA - Endologix, Inc., a developer of innovative treatments for aortic disorders, announced that Shelley Thunen, chief financial officer, has decided to resign from her position.
Ms. Thunen joined in January 2013. Prior to joining Endologix, Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. (acquired August 2010), a wholly owned Alcon company that develops and manufactures a laser and related disposable for use in cataract surgery.

Prior to the acquisition by Alcon, Ms. Thunen served as Chief Financial Officer and Vice President, Operations at that company since 2009. She also served on the LenSx Board of Directors and as chairperson of the Audit Committee from 2008 until its acquisition in 2010.

Ms. Thunen was a Board Member and chairperson of the Audit Committee for eyeonics, inc., a developer and manufacturer of accommodating intraocular lenses for the treatment of cataracts, from 2007 to 2008 until eyeonics was acquired by Bausch & Lomb, a diversified ophthalmology company.

From 2007 to 2009, Ms. Thunen was Chief Financial Officer of TherOx, Inc., a privately-held medical device company focused on cardiovascular therapeutics.

From 2004 to 2007, Ms. Thunen was Executive Vice President and Chief Financial Officer, and from 2001 to 2004 Chief Financial Officer of IntraLase Corp., a Nasdaq-listed ophthalmology company that designs, develops and manufactures the IntraLase laser and disposable product, used in LASIK surgery. IntraLase was acquired by Advanced Medical Optics, Inc., an NYSE-listed company, in 2007.

Ms. Thunen received a B.A. in Economics, cum laude, and a Masters of Business Administration (MBA), both from the University of California at Irvine.

She will continue to serve as the Company's Chief Financial Officer through the recruitment and transition process to a new CFO and will remain available to the Company as long as required to ensure a smooth and complete transition.